{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:37:02Z","timestamp":1780612622566,"version":"3.54.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.yrtph.2024.105736","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T23:12:41Z","timestamp":1730934761000},"page":"105736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Importance of tailored non-clinical safety testing of novel antimalarial drugs: Industry best-practice"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-3409","authenticated-orcid":false,"given":"Philip","family":"Hewitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Tornesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Ferry-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Desert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gresham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Demarta-Gatsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay Kumar","family":"Venishetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Kolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2024.105736_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/452539","article-title":"Patient related factors affecting adherence to antimalarial medication in an urban estate in Ghana","volume":"2015","author":"Amponsah","year":"2015","journal-title":"Malaria Research and Treatment"},{"key":"10.1016\/j.yrtph.2024.105736_bib2","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.ddtec.2012.07.003","article-title":"Humanised models of infection in the evaluation of anti-malarial drugs","volume":"10","author":"Angulo-Barturen","year":"2013","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.yrtph.2024.105736_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002252","article-title":"A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes","volume":"3","author":"Angulo-Barturen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2024.105736_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2352-4642(20)30127-9","article-title":"Treatment and prevention of malaria in children","volume":"4","author":"Ashley","year":"2020","journal-title":"The Lancet Child & Adolescent Health"},{"key":"10.1016\/j.yrtph.2024.105736_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/bdrc.20175","article-title":"In vitro developmental toxicology assays: A review of the state of the science of rodent and zebrafish whole embryo culture and embryonic stem cell assays","volume":"90","author":"Augustine-Rauch","year":"2010","journal-title":"Birth Defects Research Part C: Embryo Today: Reviews"},{"key":"10.1016\/j.yrtph.2024.105736_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/bdrb.21168","article-title":"A developmental toxicology assay platform for screening teratogenic liability of pharmaceutical compounds","volume":"107","author":"Augustine-Rauch","year":"2016","journal-title":"Birth Defects Res. Part B Dev. Reproductive Toxicol."},{"key":"10.1016\/j.yrtph.2024.105736_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/toxres\/tfaa106","article-title":"A target safety assessment of the potential toxicological risks of targeting plasmepsin IX\/X for the treatment of malaria","volume":"10","author":"Barber","year":"2021","journal-title":"Toxicology Research"},{"key":"10.1016\/j.yrtph.2024.105736_bib7","unstructured":"BLAST, NIH BLAST database https:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi."},{"key":"10.1016\/j.yrtph.2024.105736_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","article-title":"Epidemiology and infectivity of plasmodium falciparum and plasmodium vivax gametocytes in relation to malaria control and elimination","volume":"24","author":"Bousema","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.yrtph.2024.105736_bib9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yrtph.2024.105736_bib10","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cpt.2602","article-title":"Science-based approach to harmonize contraception recommendations in clinical trials and pharmaceutical labels","volume":"113","author":"Bowman","year":"2023","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.yrtph.2024.105736_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1039\/c5tx00197h","article-title":"Effects of mid-respiratory chain inhibition on mitochondrial function in vitro and in vivo","volume":"5","author":"Broom","year":"2016","journal-title":"Toxicology Research"},{"key":"10.1016\/j.yrtph.2024.105736_bib13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2024.105736_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cts.13011","article-title":"Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19","volume":"14","author":"Delaunois","year":"2021","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.yrtph.2024.105736_bib15","article-title":"Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarials","volume":"8","author":"Delaunois","year":"2024","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2024.105736_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000221","article-title":"Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study","volume":"7","author":"Dellicour","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.yrtph.2024.105736_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01574-22","article-title":"Predicting optimal antimalarial drug combinations from a standardized plasmodium falciparum humanized mouse model","volume":"67","author":"Demarta-Gatsi","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.yrtph.2024.105736_bib18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/bdr2.2190","article-title":"Integration and application of new approach methodologies in assessing the developmental hazards: case study with an antimalarial drug","volume":"115","author":"Demarta-Gatsi","year":"2023","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.yrtph.2024.105736_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12936-022-04137-2","article-title":"Re-orienting anti-malarial drug development to better serve pregnant women","volume":"21","author":"El Gaaloul","year":"2022","journal-title":"Malar J."},{"key":"10.1016\/j.yrtph.2024.105736_bib20","article-title":"Food and Drug Administration. Draft guidance, pregnant women: scientific and ethical considerations for inclusion in clinical trials","year":"2018","journal-title":"Fed. Regist."},{"key":"10.1016\/j.yrtph.2024.105736_bib21","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1002\/1873-3468.13868","article-title":"The cytochrome bc(1) complex as an antipathogenic target","volume":"594","author":"Fisher","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.yrtph.2024.105736_bib74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/toxsci\/kfae086","article-title":"Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitors","volume":"201","author":"Gerets","year":"2024","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.yrtph.2024.105736_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd.2015.34","article-title":"Evolution of strategies to improve preclinical cardiac safety testing","volume":"15","author":"Gintant","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105736_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/aivt.2017.0008","article-title":"Use of alternative developmental toxicity assays to assess teratogenicity potential of pharmaceuticals","volume":"4","author":"Green","year":"2017","journal-title":"Applied In Vitro Toxicology"},{"key":"10.1016\/j.yrtph.2024.105736_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116006","article-title":"An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2","volume":"443","author":"Hewitt","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105736_bib27","series-title":"ICH Consensus Guideline","article-title":"ICH S7A. Safety pharmacology studies for human pharmaceuticals","year":"2000"},{"key":"10.1016\/j.yrtph.2024.105736_bib28","article-title":"ICH S7B. Nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability","year":"2005","journal-title":"ICH Consensus Guideline"},{"key":"10.1016\/j.yrtph.2024.105736_bib30","article-title":"M3 (R2) - questions and answers","year":"2011","journal-title":"EMA\/CHMP\/ICH\/507008\/2011"},{"key":"10.1016\/j.yrtph.2024.105736_bib32","article-title":"ICH M3(R2). Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticalstle","year":"2013","journal-title":"ICH Consensus Guideline"},{"key":"10.1016\/j.yrtph.2024.105736_bib75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bcp.13438","article-title":"Inclusion of pregnant and breastfeeding women in research - efforts and initiatives","volume":"84","author":"Illamola","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105736_bib39","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/bdr2.2001","article-title":"A novel human stem cell-based biomarker assay for in vitro assessment of developmental toxicity","volume":"114","author":"Jamalpoor","year":"2022","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.yrtph.2024.105736_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106869","article-title":"A practical guide to secondary pharmacology in drug discovery","volume":"105","author":"Jenkinson","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"Suppl. 1","key":"10.1016\/j.yrtph.2024.105736_bib41","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1475-2875-8-S1-S2","article-title":"Ongoing challenges in the management of malaria","volume":"8","author":"Kokwaro","year":"2009","journal-title":"Malar. J."},{"key":"10.1016\/j.yrtph.2024.105736_bib42","doi-asserted-by":"crossref","first-page":"14121","DOI":"10.1021\/acs.jmedchem.2c01336","article-title":"Discovery and characterization of potent, efficacious, orally available antimalarial plasmepsin X inhibitors and preclinical safety assessment of UCB7362","volume":"65","author":"Lowe","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.yrtph.2024.105736_bib43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.vascn.2017.02.020","article-title":"Potential functional and pathological side effects related to off-target pharmacological activity","volume":"87","author":"Lynch","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2024.105736_bib44","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1128\/AAC.02883-15","article-title":"Linking murine and human plasmodium falciparum challenge models in a translational path for antimalarial drug development","volume":"60","author":"McCarthy","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.yrtph.2024.105736_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1562\/0031-8655(1999)069<0282:PSOAD>2.3.CO;2","article-title":"Photophysical studies on antimalarial drugs","volume":"69","author":"Motten","year":"1999","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.yrtph.2024.105736_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106917","article-title":"Is there a role for the no observed adverse effect level in safety pharmacology?","volume":"105","author":"Mow","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2024.105736_bib47","article-title":"Test No. 432: in vitro 3T3 NRU phototoxicity test","volume":"4","year":"2019","journal-title":"OECD Guidelines for the Testing of Chemicals, Section"},{"key":"10.1016\/j.yrtph.2024.105736_bib48","article-title":"Test No. 495: ros (reactive oxygen species) assay for photoreactivitytle","volume":"4","year":"2019","journal-title":"OECD Guidelines for the Testing of Chemicals, Section"},{"key":"10.1016\/j.yrtph.2024.105736_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02181-19","article-title":"Preclinical antimalarial combination study of M5717, a plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor","volume":"64","author":"Rottmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.yrtph.2024.105736_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10928-015-9413-5","article-title":"The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments","volume":"42","author":"Sahota","year":"2015","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.yrtph.2024.105736_bib51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(22)01881-5","article-title":"Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis","volume":"401","author":"Saito","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2024.105736_bib52","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.008662","article-title":"Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection","volume":"13","author":"Saleh","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.yrtph.2024.105736_bib76","first-page":"186","article-title":"Malaria and pregnancy: a global health perspective","volume":"2","author":"Schantz-Dunn","year":"2009","journal-title":"Rev. Obstet. Gynecol."},{"key":"10.1016\/j.yrtph.2024.105736_bib53","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nprot.2011.348","article-title":"The validated embryonic stem cell test to predict embryotoxicity in vitro","volume":"6","author":"Seiler","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.yrtph.2024.105736_bib54","first-page":"624","article-title":"The laboratory rat: relating its age with human's","volume":"4","author":"Sengupta","year":"2013","journal-title":"Int. J. Prev. Med."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105736_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5005\/jp-journals-10006-2401","article-title":"Inclusion of pregnant women in clinical trials: need, ethical and scientific considerations and current status","volume":"16","author":"Shaikh","year":"2024","journal-title":"J South Asian Feder Obs Gynae"},{"key":"10.1016\/j.yrtph.2024.105736_bib56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/2168479015608415","article-title":"Birth control in clinical trials: industry survey of current use practices, governance, and monitoring","volume":"50","author":"Stewart","year":"2016","journal-title":"Ther Innov Regul Sci."},{"key":"10.1016\/j.yrtph.2024.105736_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2024.105736_bib58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.4.3.421","article-title":"Antimalarial drugs: QT prolongation and cardiac arrhythmias","volume":"4","author":"Traebert","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yrtph.2024.105736_bib59","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.3389\/fimmu.2018.02550","article-title":"Humanized mice are instrumental to the study of plasmodium falciparum infection","volume":"9","author":"Tyagi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yrtph.2024.105736_bib60","article-title":"Report to congress","year":"2020","journal-title":"Task Force on Research Specific to Pregnant Women and Lactating Women - Report Implementation Plan"},{"key":"10.1016\/j.yrtph.2024.105736_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.vascn.2018.07.001","article-title":"In vitro secondary pharmacological profiling: an IQ-DruSafe industry survey on current practices","volume":"93","author":"Valentin","year":"2018","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.yrtph.2024.105736_bib62","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: a Pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.yrtph.2024.105736_bib78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(07)70187-1","article-title":"Cardiotoxicity of antimalarial drugs","volume":"7","author":"White","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.yrtph.2024.105736_bib64","series-title":"Guidelines for the Treatment of Malaria","year":"2015"},{"key":"10.1016\/j.yrtph.2024.105736_bib66","series-title":"World Malaria Report 2021","year":"2021"},{"key":"10.1016\/j.yrtph.2024.105736_bib70","series-title":"World Malaria Report 2023","year":"2023"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T03:18:40Z","timestamp":1733282320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024001776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":59,"alternative-id":["S0273230024001776"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105736","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importance of tailored non-clinical safety testing of novel antimalarial drugs: Industry best-practice","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105736"}}